KADS Trial: Subcutaneous Ketamine Proves Effective for Treatment-Resistant Depression By Depression, TRDA recent active-controlled trial using subcutaneous ketamine injections over four weeks has demonstrated strong efficacy…Read More June 17, 2025
Optimizing Ketamine Frequency: A Double-Blind Study on Dosing Strategies in Treatment-Resistant Depression By DepressionIn the landmark study A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients…Read More June 4, 2025